<DOC>
	<DOCNO>NCT00204230</DOCNO>
	<brief_summary>Prospective , randomise study : Effect mycophenolatmofetil ( MMF ) CNI withdrawal patient histologically proven chronic allograft nephropathy Indication : change immunosuppressive treatment chronic allograft nephropathy ( CAN ) renal transplantation Hypothesis : Antimetabolite MMF able stop progression CAN improve blood pressure/ metabolic parameter structural vessel wall change Primary Target : effect CNI withdrawal MMF renal function : stabilisation and/or improvement Secondary Targets : Incidence adverse event Evaluation calcineurin inhibitor free MMF treatment effect blood pressure , lipid , glucose metabolism structural functional vesselwallchanges Method : open prospective , randomize two-tailed , monocentric study</brief_summary>
	<brief_title>MMF Calcineurin Inhibitor Withdrawal CAN</brief_title>
	<detailed_description>Prospective , randomise study : Effect mycophenolatmofetil patient histologically proven chronic allograft nephropathy SYNOPSIS Indication : change treatment improve course chronic allograft nephropathy Method : open prospective , randomize two-tailed , non blind monocentric study Follow period : 35 Weeks Number patient : 2 x 86 patient Inclusion criterion : • Written inform consent - Reduction graft function : Increase serum creatinine &gt; /= 0,1mg/dl/month previous 6 month start study and/or new occurrence increase proteinuria last 6 month start study - Serum creatinine &lt; 4 mg/dl - Biopsy within last 3 month - histologically prove chronic allograft nephropathy ( graft glomerulopathy , chronic rejection , interstitial fibrosis , tubular atrophy , vascular arteriosclerosis , hyalinosis ) - &gt; 1 year renal allografting - At least 5 mg/day prednisolone equivalent dose Exclusion criterion : • Malignomas - Gravidity Lactation - Participation study - Severe infection - Florid gastrointestinal Ulcer - Age 18 70 year - Leukopenia le 3000/l leucocyte , Anaemia Hb  9 g/dl - Therapy mycophenolatmofetil past 6 month - Acute rejection apst 6 month Study protocol : Phase I : Week 1.-3 . Conversion Triple-Drug-Therapy , consist Mycophenolatmofetil , corticosteroid ( e.g . prednisolone ) ciclosporine A Tacrolimus 1 . Addition Mycophenolatmofetil ( MMF ) previous immosuppressive treatment , consist ciclosporine A ( CsA ) Tacrolimus ( FK506 ) combination corticosteroid , e.g . prednisolone ( P ) . In case azathioprine ( AZA ) give , AZA replace MMF . The therapy MMF start 3 day elimination azathioprine . The addition MMF follow follow scheme nothing else indicate : 1. week : 1g/day , 2.week : 1,5g/day , 3.week : 2g/day 2 . Ciclosporine A bzw . tacrolimus : Target whole trough blood level : CsA : 80-120 ng/ml ( HPLC ) FK506 : 4-7 ng/ml ( IMX Tacrolimus , Abbott ) 3 . Corticosteroids , e.g . prednisolone : The previous dosage continue , least 5 mg prednisolone/day ( equivalent ) must give Phase II : week 4.-9 . Randomisation begin week 4 : All patient receive least 3 x 500 mg MMF per day randomise follow Group A : Continuation triple therapy Group B : Elimination CsA bzw . FK506 The ciclosporine A- tacrolimus-dosage reduce ba 33 % 2 week 6-8 week total elimination drug reach . Phase III : week 10.-35 . Continuous therapy ... : Group A : Triple therapy MMF / CsA bzw . FK506 / Corticosteroids e.g . Prednisolone Group B : Dual therapy MMF / Corticosteroids e.g . Prednisolone Primary Endpoint : Comparison development 1/creatinine branch 32 week randomization Secondary Endpoints : - Occurrence ... - acute rejection - infection - malignomas - gastrointestinal disorder - Blood pressure evolution number antihypertensive drug - Changes concern lipid state - Changes concern glucose metabolism - Changes metabolism uric acid - Comparison development 1/creatinine within branch 6 month 6 month therapy conversion - Comparison drop rate branch A und B - Pharmacokinetics mycophenolic acid ( MPA ) base new method abbreviate area curve ( AUC ) determination - vessel wall change carotid artery measure high resolultion ultrasound method hemodynamic parameter measure task force equipment 9 month cni withdrawal MMF addition Criteria study discontinuation : - Sepsis - Occurrence acute rejection - Graft loss - Other severe adverse event - patient decision</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Written inform consent Reduction graft function : Increase serum creatinine &gt; = 0,1mg/dl/month previous 6 month start study and/or new occurrence increase proteinuria last 6 month start study Serum creatinine &lt; 4 mg/dl Biopsy within last 3 month histologically prove chronic allograft nephropathy &gt; =1 year renal allografting &gt; =5 mg/day Prednisolone equivalent dose Malignomas Gravidity Lactation Participation study Severe infection gastrointestinal Ulcer Age &lt; 18 &gt; 70 year Leukopenia less 3000/dl leucocyte , Anaemia Hb &gt; 9 g/dl Therapy mycophenolatmofetil past 6 month Acute rejection past 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Kidney Failure , Chronic</keyword>
	<keyword>Kidney Transplantation</keyword>
</DOC>